Adlai Nortye Stock
Adlai Nortye Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Singapore
- CEO
- Yang Lu
- Employees
- 109
- Market cap
- $585 M
- IPO
- 29/09/2023
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential…
Adlai Nortye stock: price history
1D
-8.8%
1W
-29.4%
1M
-28.9%
6M
-31.1%
YTD
+676.8%
1Y
+585.1%
2Y
+465.6%
5Y
–
10Y
–
Next earnings date
Next earnings date
03/03/2027 (in 137 days)
Volatility around earnings
~8% stronger price swings than usual
Adlai Nortye stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 18/08/2026.
Ask the agents about Adlai Nortye
Analyst assessment of Adlai Nortye
PRICE TARGET LOW
US$20.00
CONSENSUS
US$33.00
MEDIAN
US$31.50
PRICE TARGET HIGH
US$49.00
0
STRONG BUY
1
BUY
0
HOLD
0
SELL
0
STRONG SELL
1
TOTAL · Buy
As of: 08/09/2026
Adlai Nortye stock metrics
P/E
-5.64
P/B
0.82
EV/EBITDA
-22.82
RETURN ON EQUITY
-1.2%
NET MARGIN
-36.3%
DEBT/EQUITY
0.12
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
71.2%
FLOAT SHARES
12,596,238
AVG. DAILY VOLUME (30D)
271,701
Insider transactions (SEC)
Ji Ping
Ji Ping
Ji Ping
Ji Ping
Ye Xiaofeng
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -8.8%
Search (Google Trends)
Forums (Reddit)
Institutional holders
Comparable stocks
Frequently asked questions about Adlai Nortye stock
What does Adlai Nortye do?
Adlai Nortye Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Singapore.
The CEO is Yang Lu, the company employs around 109 people.
The IPO was on 29/09/2023; the stock trades on NASDAQ under the ticker ANL.
What do analysts say about Adlai Nortye stock?
1 analysts rate the stock, the consensus is Buy (as of 08/09/2026).
The average price target is US$33.00, ranging from US$20.00 to US$49.00, with a median of US$31.50.
This is an external assessment, not a statement by Market Jury.
When does Adlai Nortye report next?
The next earnings date is 03/03/2027.
Around past earnings, price swings were roughly 8% stronger than usual.
Does Adlai Nortye pay a dividend?
No, Adlai Nortye currently does not pay a dividend.
Which stocks are comparable to Adlai Nortye?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get Adlai Nortye stock analyzed?
Clicking "Analyze stock" lets five strategies assess Adlai Nortye against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.